{
  "content": ". Perhaps more relevant to the use of the intravenous formulation is the pharmacodynamic interactions between amiodarone and a variety of drugs that slow the sinus node and retard conduction through the AV node, including beta-adrenergic and calcium channel blocking agents as well as digitalis ([28, 29]). This is particularly relevant in the treatment of patients with underlying conduction system disease.",
  "source": "https://www.jacc.org/doi/10.1016/S0735-1097%2897%2900069-7",
  "chunk_id": "9982e215-f1d5-47a8-b1b6-ee7a43b94eba",
  "similarity_score": 0.2640327215194702,
  "query": "amiodarone drug interactions contraindications beta-blockers digoxin warfarin CYP450 metabolism",
  "rank": 47,
  "title": "Intravenous amiodarone",
  "authors": "Peter R Kowey, MD, FACC; Roger A Marinchak, MD, FACC; Seth J Rials, MD, PhD, FACC; Roland A Filart, MD, FACC",
  "year": "1997",
  "journal": "Journal of the American College of Cardiology",
  "reference": "Kowey, P. R., Marinchak, R. A., Rials, S. J., & Filart, R. A. (1997). Intravenous amiodarone. Journal of the American College of Cardiology, 29(6), 1190â€“1198.",
  "doi": "Not available",
  "chunk_index": 14,
  "total_chunks": 118,
  "retrieved_at": "2025-07-24T22:33:49.726062"
}